Phase 1 Metastatic Castration-resistant Prostate Cancer Clinical Trials

59 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 120 of 59 trials

Recruiting
Phase 1

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Metastatic Castration-resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer ( SCLC )Follicular Lymphoma ( FL)
Pfizer453 enrolled83 locationsNCT03460977
Recruiting
Phase 1

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (mCRPC)
Amgen40 enrolled3 locationsNCT07493512
Recruiting
Phase 1

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Breast CancerCervical CancerColon Cancer+4 more
Orano Med Theranostics, SAS48 enrolled8 locationsNCT05283330
Recruiting
Phase 1

Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer

Metastatic Castration-resistant Prostate CancerAdvanced Prostate AdenocarcinomaPSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer+1 more
Beijing Biotech36 enrolled1 locationNCT07641049
Recruiting
Phase 1Phase 2

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)
Pathos AI, Inc.120 enrolled18 locationsNCT06785636
Recruiting
Phase 1Phase 2

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

Metastatic Castration-resistant Prostate Cancer (mCRPC)
Arsenal Biosciences, Inc.190 enrolled9 locationsNCT07285694
Recruiting
Phase 1Phase 2

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals205 enrolled9 locationsNCT07288359
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

Advanced Metastatic Castration-resistant Prostate Cancer
Shenzhen Ionova Life Sciences Co., Ltd.84 enrolled22 locationsNCT06609005
Recruiting
Phase 1

Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T

Metastatic Castration-resistant Prostate Cancer (mCRPC)
National Taiwan University Hospital12 enrolled2 locationsNCT07621692
Recruiting
Phase 1

A Phase I Trial of A-CAR032 in Participants With mCRPC

Prostate CancerMetastatic Castration-resistant Prostate Cancer
Shanghai AbelZeta Ltd.27 enrolled5 locationsNCT07344311
Recruiting
Phase 1

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals208 enrolled2 locationsNCT07570979
Recruiting
Phase 1Phase 2

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Colorectal, CancerProstate CancerCancer+12 more
Parabilis Medicines, Inc.595 enrolled33 locationsNCT05919264
Recruiting
Phase 1

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 1

Study With [225Ac]Ac-FL-020 in mCRPC Participants

Metastatic Castration-resistant Prostate Cancer
Full-Life Technologies UK Limited50 enrolled11 locationsNCT06492122
Recruiting
Phase 1

A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate CancerAdvanced or Metastatic Adrenocortical Carcinoma
Daiichi Sankyo40 enrolled6 locationsNCT07189403
Recruiting
Phase 1Phase 2

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Prostate CancerMetastatic Castration-resistant Prostate CancerUrogenital Neoplasms+3 more
Blue Earth Therapeutics Ltd82 enrolled21 locationsNCT05413850
Recruiting
Phase 1

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer
Daiichi Sankyo60 enrolled19 locationsNCT07244341
Recruiting
Phase 1

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer
AstraZeneca136 enrolled16 locationsNCT06879041
Recruiting
Phase 1

A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)Castration Resistant Metastatic Prostate Cancer+2 more
Aktis Oncology, Inc.138 enrolled2 locationsNCT07581184
Recruiting
Phase 1Phase 2

ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium

Prostate CancerMetastatic Prostate CancerMetastatic Castration-resistant Prostate Cancer
University College, London60 enrolled1 locationNCT07414940